Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:1/26/2009

s a real medical need for a treatment which we hope to address," added Kamel Besseghir, CEO of Debiopharm S.A.

About Debio 025

Debio 025 is a synthetic first-in-class Cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in the following preclinical and clinical studies. Results of a phase Ib study demonstrate that Debio 025 monotherapy for 15 days induced a strong anti-HCV effect (3.6 log10 reduction) in HIV-1/HCV co-infected patients. (Hepatology, 47:817-26). Results of a phase IIa study with Debio 025 indicate that Debio 025 shows an important additive anti-HCV effect (4.6 log10 reduction) when co-administered with peg-IFNalpha2a to treatment-naive HCV patients. (J Hepatol, 48: S2)

About HCV

HCV, in combination with hepatitis B, now accounts for 75% of all cases of liver disease around the world. HCV is considered by the World Health Organization as an epidemic. Because HCV can infect a patient for decades before being discovered, it is often called the "silent" epidemic. Studies suggest that in the US alone, nearly 4 million people are or have been infected with HCV and of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulatio
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Quantum Materials ... diverse sets of patent families from Bayer Technology Services ... driver for Bayer AG of Leverkusen, ... acquired provide broad intellectual property protection for advances ... high-volume quantum dot (QD) manufacturing. In addition, the ...
(Date:8/20/2014)... MUMBAI , August 20, 2014 ... owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), ... studies of a novel clinical development candidate, GBR ... discovered and developed by the Glenmark Biologics Research ... . GBR 1302 is based on Glenmark,s ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... to Differentiate Squamous From, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying Squamous Cell, ... ... Percent., Accurate Diagnosis is Important for Guiding ... Rates of Severe or Fatal Hemorrhage in Patients With Squamous NSCLC ...
... California, April 3 ,Results of an independent ... the first clinically proven non-invasive solution,for fat ... focused,ultrasound will be presented at the American ... on April 4, 2008 in Kissimmee, Florida. ...
Cached Medicine Technology:Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 2Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 3Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 4Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 5Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 6Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 7UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting 2UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting 3
(Date:8/20/2014)... OR (PRWEB) August 20, 2014 August ... are urged to become educated about eye health and ... examined. One frequently overlooked eye condition that must be ... Sharon Kleyne Hour Power of Water radio show, is ... children increasing exponentially, childhood dry eye is becoming a ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
(Date:8/20/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... System in Hermiston, Ore. The top executive search ... has recently placed more than 900 healthcare executives into ... a progressive, not-for-profit healthcare organization serving a population of ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Oxnard ... founder of the Anacapa Dental Art Institute, is presenting ... Dr. Jivraj will be speaking on All-on-4 dental ... Aspects of Graft Less Solutions” at 12:40 p.m. Sept. ... in Vancouver, British Columbia, Canada. , “The All-on-4 procedure ...
(Date:8/20/2014)... Washington, DC (PRWEB) August 20, 2014 ... Got Heart, Give Hope® Celebration to be hosted in ... Army and Navy Club. This signature event honors the ... the families of the fallen. Proceeds from the Got ... Warriors®, a national nonprofit dedicated to restoring a sense ...
Breaking Medicine News(10 mins):Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 2Health News:Internationally Known Oxnard Dentist to Speak at Conference in Vancouver 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2
... MENLO PARK, Calif., Oct. 23 SRI International, ... today that Dr. Elizabeth Shriberg, a senior researcher ... has been named a Fellow of the International ... at Interspeech 2009 in Brighton, England, recognizes significant ...
... SILVER SPRING, Md., Oct. 23 The U.S. Food ... a request from the U.S. Centers for Disease Control ... (EUA) for the investigational antiviral drug peramivir intravenous (IV) ... suspected 2009 H1N1 influenza infection who are admitted to ...
... International Dairy Foods Association applauded Agriculture Secretary Tom Vilsack ... offering more low fat milk and dairy products in ... improve the quality of school meals, one of the ... outlined the Obama Administration,s agenda for Child Nutrition Act ...
... Singer/Songwriter Patti Austin Headline Annual Andrus Awards Gala ... leadership in communication , LAS VEGAS, Oct. 24 ... to acclaimed television pioneer Norman Lear at a celebration ... and expo. Lear, creator of shows including " All in the ...
... Surgery 2009 News Briefs are designed to keep you ... at the annual meeting of the American Society of ... briefs are embargoed until the date/time they are presented. ... for media registration, or to arrange interviews with presenters, ...
... that injection sting is excessive disputed in U.S. study , ... that injections of the human papillomavirus (HPV) vaccine are especially ... more than any other shots. , Public health officials worried ... getting the vaccine, which protects against a virus that can ...
Cached Medicine News:Health News:SRI International Researcher Receives International Speech Communication Association (ISCA) Fellow Award 2Health News:SRI International Researcher Receives International Speech Communication Association (ISCA) Fellow Award 3Health News:FDA Authorizes Emergency Use of Intravenous Antiviral Peramivir for 2009 H1N1 Influenza for Certain Patients, Settings 2Health News:IDFA Supports Obama Administration's Commitment to Encourage Schools to Provide More Low Fat Milk and Dairy Products in Schools 2Health News:Legendary TV Producer Norman Lear Receives AARP's Highest Honor 2Health News:Legendary TV Producer Norman Lear Receives AARP's Highest Honor 3Health News:Plastic Surgery 2009 news briefs 2Health News:Plastic Surgery 2009 news briefs 3Health News:Plastic Surgery 2009 news briefs 4Health News:Plastic Surgery 2009 news briefs 5Health News:Plastic Surgery 2009 news briefs 6Health News:HPV Vaccine No More Painful Than Other Shots 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: